VedaBio develops the CRISPR Cascade platform for molecular detection, enabling ultra-rapid and highly multiplexed analysis of nucleic acid targets. This technology provides high accuracy without requiring target amplification, significantly speeding up analytical reaction times. The platform offers rapid reprogramming for new targets, expanding possibilities across various diagnostic applications.
Funding
$29.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OVFounders
Product
Problem
Traditional molecular detection methods like PCR require target amplification, which can be time-consuming and limit the scalability of multiplexed assays. These limitations hinder rapid and high-throughput analysis in various diagnostic and research applications.
Solution
VedaBio's CRISPR Cascade™ platform offers a novel approach to molecular detection by utilizing engineered CRISPR enzymes for direct detection of nucleic acid targets, eliminating the need for target amplification. This platform employs a positive signal amplification feedback loop triggered by target recognition, enabling ultra-rapid analytical reaction times. The CRISPR Cascade™ is designed for high-performance, highly scalable, and rapid assays, allowing for the pooling of multiple targets within reactions, facilitating massive multiplexing capabilities.
Target Audience
The primary audience includes researchers and diagnostic developers seeking rapid, accurate, and highly multiplexed molecular detection solutions.
Features
- Target amplification-free molecular detection using engineered CRISPR enzymes, blocked sequences, and reporter molecules
- Ultra-rapid analytical reaction times, with results in minutes
- High multiplexing capability, enabling the simultaneous detection of multiple targets
- Rapid reprogramming for new targets through simple target sequence selection and optimization